Nivolumab is an immune checkpoint inhibitor (ICI), which is used for treatment of advanced malignancies. Diarrhea is a typical adverse effect of ICIs. Several endoscopic features of ICI-related colitis have been reported. Herein, we reported a case of ICI-related colitis, with successful follow-up using ultrasonography (US). A 54-year-old woman, diagnosed with renal cell carcinoma, underwent radical nephrectomy. Multiple liver and bone metastases appeared 6 months after surgery. She was prescribed sunitinib, which was discontinued, because of severe diarrhea. She was prescribed nivolumab after 1 week. However, she was hospitalized 9 days later, due to fever and diarrhea. US showed diffuse wall thickening from the cecum to the rectum. The wall layer structures were preserved, and thickening was observed mainly in the submucosa, but not in the mucosa, without a decrease in the echo level. Subsequently, sigmoidoscopy was performed. Severe edema was observed in the mucosa, without any erosion and granularity. She was clinically diagnosed with ICI-related colitis, and steroid therapy was administered. One week after steroid therapy, the diarrhea improved, and the earlier findings showed marked improvement on US. After another week of reduced steroid dose, US revealed further improvement, and she was discharged.
Introduction
Immune checkpoint inhibitors (ICI) have been newly introduced for the treatment of advanced malignancies, such as melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin's lymphoma, and squamous cell carcinomas of the head and neck. ICIs are expected to find applications in the treatment of a wider range of diseases in the future.
However, ICIs can cause immune-related adverse events (irAE). Colitis is a well-known irAE, for which a variety of colnoscopy (CS) findings have been reported [1, 2] . Moreover, transabdominal ultrasonography (US) has recently been used for diagnosing and following-up on gastrointestinal diseases [3, 4] . Herein, we reported our experience with ICIrelated colitis and successful followed-up with US. and right back pain. Computed tomography (CT) revealed a tumor approximately 50 mm in size in the right kidney, and renal cell carcinoma was strongly suspected. She was treated with right radical nephrectomy. The pathological diagnosis was stage T1b clear cell renal cell carcinoma with sarcomatoid features. Multiple liver and bone metastases appeared 6 months after surgery. She was started on sunitinib, which was discontinued after 2 weeks, owing to severe grade 3 diarrhea, as defined by the Common Terminology Criteria for Adverse Events (CTCAE) [5] . She improved 1 week after discontinuation of sunitinib and was prescribed nivolumab. However, she experienced fever and diarrhea 7 days after the infusion and required hospitalization. The laboratory findings at initiation of therapy revealed slight anemia, elevation of the C-reactive protein levels, and erythrocyte sedimentation rate (Table 1) . Nivolumab was discontinued because she was diagnosed with CTCAE grade 3 diarrhea. She was started on conservative therapy. However, the diarrhea gradually worsened. The clinical course is presented in Fig. 1 .
Initial US showed diffuse wall thickening from the cecum to the rectum. The layered structure of the wall was intact, and thickening was observed mainly in the submucosa. Moderately hypoechoic changes were observed in the submucosa. A few hypoechoic changes were observed in the mucosal layer. The mucosal surface was smooth, and no depressed lesions suggestive of ulceration were found. The color Doppler signal was increased in the submucosa. Mesenteric vessel engorgement and increased blood flow signal were observed in the transverse colon and sigmoid colon ( Fig. 2) . Initial contrast-enhanced CT revealed edematous changes from the descending colon to the rectum (Fig. 3a) . Ischemic colitis was cited as a differential diagnosis. However, the maintenance of bowel wall enhancement was an atypical observation. Sigmoidoscopy was performed for the sigmoid colon and rectum. Severe edema was observed in the mucosa, without granularity, ulceration, and erosion ( Fig. 4a, b) .
The patient was clinically diagnosed with ICI-related colitis. She was administered intravenous steroid treatment with prednisolone (PSL) 60 mg/day, after which the diarrhea improved. There was a marked improvement in the wall thickening on the second US performed 1 week after treatment, although a few local areas of wall thickening remained. Therefore, the dose of PSL was reduced to 40 mg/day. CS, which was performed the following day ( Fig. 4c, d ), showed that normal mucosa was interspersed between areas of edema; the edematous mucosa was not continuous. Pathological examination of the biopsy specimens revealed lymphocytic aggregation. However, the specific features of other types of colitis, such as, crypt abscesses and basal plasmacytosis, which are observed in ulcerative colitis, were absent. These lymphocytes were positive for CD3, CD4, and CD8. CD68 positive macrophages were also present, instead of neutrophils ( Fig. 5 ). However, no specific features of mucosal inflammation were observed. Specific infectious colitis and cytomegalovirus infection were excluded from the diagnosis. The third US, performed 1 week after the second US, showed further improvement in wall thickening. The effects of ICI-related colitis treatment on the US findings are shown in Fig. 6a -c. The dose of PSL was further reduced to 30 mg/day, and the patient was discharged. The second CT revealed improvement in wall thickening, and the edematous change had disappeared ( Fig. 3b ). However, about 520 days after the first nivolumab administration, CT revealed exacerbation of the multiple liver metastases. One week after CT, the patient visited the hospital with a complaint of abdominal fullness and was hospitalized on the same day. According to her request, the second administration of nivolumab was started. However, after completing two courses of treatment, her condition became worsened and she died.
Discussion
ICIs act on the anti CTLA-4 antibody (ipilimumab and tremelimumab), anti PD-1 antibody (pembrolizumab and nivolumab), and anti PD-L1 antibody (atezolizumab, avelumab, and durvalumab). The reported frequency and onset of irAE were different for each drug and the type of disease treated [5, 6] . The rate of incidence of the colitis caused by ipilimumab therapy is higher than that of anti PD-1 and anti PD-L1 inhibitors [6, 7] . Wang et al. reported that the rate of incidence of colitis during ipilimumab and anti PD-1/PD-L1 inhibitor monotherapy were 9.1% and 1.3%, respectively [7, 8] . On the other [8, 9] . The severity of colitis caused by ICI therapy is graded on a scale of 1 to 5 (1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, and 5 = death related to toxicity) using the CTCAE. Continuation and discontinuation may be recommended by the American Society of Clinical Oncology Clinical Practice guidelines [10] and ESMO Clinical Practice Guidelines [11] for the diagnosis of the severity of irAE. The American Society of Clinical Oncology Clinical Practice guidelines for managing irAE provide All ICI treatment should be permanently discontinued for grade 4 toxicities. This patient was diagnosed with CTCAE grade 3 diarrhea, and ICI was temporarily discontinued. After the symptoms subsided, nivolumab was re-administered according to her request. Previous research on patients with NSCLC for whom nivolumab was discontinued due to irAE, explored the clinical differences between discontinuation and retreatment with nivolumab. The median overall survival (OS) and progression-free survival (PFS) did not differ significantly between retreatment and discontinuation in both studies [12, 13] . Mouri et al. reported that the median OS and PFS did not differ significantly between retreatment and discontinuation. They also reported that retreatment slightly improved the efficacy, without a significant increase in irAE. However, their study population was small, which only included patients with NSCLC; it is still unclear whether retreatment with ICIs is more effective than discontinuation. Santini et al. reported that PFS and OS were longer in the retreatment cohort, among patients with no observed partial responses prior to the irAE. Conversely, PFS and OS were similar in the retreatment and discontinuation cohorts for patients with objective responses prior to the irAE. CT and CS are Kim et al. reported two distinct patterns of ipilimumab-associated colitis on CT [9, 14] . The first is the diffuse colitis pattern, characterized by mesenteric vessel engorgement, with mild diffuse bowel wall thickening or fluid-filled distension of the colon. The second pattern is segmental colitis, associated with diverticulosis, which is characterized by moderate segmental and circumferential wall thickening in the sigmoid colon, in the area of preexisting diffuse diverticulosis, and mesenteric vessel engorgement. Since wall thickening from the cecum to the rectum was observed in our patient, it can be classified as the first (diffuse colitis) pattern. However, the disadvantages of CT include radiation exposure and limited availability [10, 11, 15, 16] . On the other hand, the myriad advantages of US include lack of radiation exposure, non-invasiveness, and costeffectiveness [12, 17] . US has recently garnered interest as a useful imaging modality for the diagnosis and follow-up of inflammatory bowel disease [4, [13] [14] [15] [18] [19] [20] . A PubMed search for studies published from inception to April 2019, with the terms "ultrasonography," "immune checkpoint inhibitor," and "colitis," revealed a lack of reports detailing the US findings of ICI-related colitis. In our case, US helped to identify the site and extent of the lesion, the degree of wall thickening, wall layer structure, echo level of the wall, increased color Doppler signal of the wall, and mesenteric vessel engorgement. These signs showed improvement after steroid therapy. Thus, US was useful for the diagnosis and follow-up of ICI-related colitis.
Some reports have documented the CS findings of ICI-related colitis. Kubo colitis [16, 17, 21, 22] . Gonzalez et al. who examined the biopsy specimens of 20 patients with diarrhea caused by treatment with anti PD-1/PD-L1 antibody reported that knowledge of the patient's clinical history was valuable, since the histological findings were fairly non-specific [18, 23] . In our case, non-specific inflammation, with CD4 and CD8 positive T lymphocyte proliferation was observed within the crypts, on pathological examination. Immunostaining for these lymphocytes may be needed to understand the relationship with the underlying mechanism of ICI-related colitis, as well as that with T helper 17 cells.
The specific US findings of ulcerative colitis started with mucosal inflammation, low echoic wall thickening, which progressed to the deeper layers. Hyperechoic shallow concavities, which reflected ulcers in the mucosal surface, were found in some cases. While the US/CS findings in our case were diffuse wall thickening from the cecum to the rectum without distinctive mucosal inflammation, the mucosal surface was relatively smooth. Moreover, discontinuity of wall thickness was seen. These findings differed from those of typical ulcerative colitis.
These differences could be attributed to the inherent difference among the ICIs. However, administration of the same ICI may cause acute or chronic colitis, for which the US/CS findings may be different. Based on the non-specificity of the mucosal findings, US may be more useful for evaluating ICIrelated colitis than CS, because US can evaluate the submucosal surfaces, which may demonstrate T cell positive lymphocyte proliferation. The specific US characteristic findings of ICI-related colitis should be investigated by correlating those observed on a multitude of cases.
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